source
- Study finds Lilly's obesity drug Zepbound may lower hospital and ER costs for older adultsA real‑world analysis examined older patients with obesity or excess weight who were either treated with Eli Lilly’s drug Zepbound or not. The researchers tracked healthcare utilization over time t…
- BMS terminates Cellares partnership after cell therapy platform fails to meet Breyanzi production needs, prompting layoffsBristol Myers Squibb has ended its collaboration with manufacturing specialist Cellares after the Cell Shuttle system could not satisfy the requirements for producing the approved CAR‑T therapy Bre…